Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Department of Surgery, Tokyo Medical University, Tokyo, Japan.
Eur J Cardiothorac Surg. 2022 Jul 11;62(2). doi: 10.1093/ejcts/ezac055.
Segmentectomy can provide oncologically acceptable results for small-sized non-small-cell lung cancer (NSCLC). However, in cases of NSCLC with pathological invasive characteristics such as lymphatic invasion (LY), vascular invasion (V), pleural invasion (PL) and/or lymph node metastasis, the feasibility of segmentectomy is not known.
The patients included in the study (i) underwent lobectomy or segmentectomy for NSCLC with invasive characteristics such as LY, V, PL or pathological lymph node metastasis; (ii) presented with a node-negative, solid component-predominant tumour (consolidation tumour ratio >50%) on preoperative computed tomography; (iii) had a whole-tumour size of 2 cm or less; and (iv) presented between January 2010 and December 2019 to one of the 3 institutions. Cumulative incidences of recurrence (CIRs) after segmentectomy and lobectomy were compared.
A total of 321 patients were included. Segmentectomy and lobectomy were performed in 80 (24.9%) and 241 (75.1%) patients, respectively. There was no significant difference in CIR between segmentectomy (5-year CIR rate, 17.2%) and lobectomy patients (5-year CIR rate, 27.8%, P = 0.135). In the propensity score-matched cohort, there was no significant difference in CIR between segmentectomy (5-year CIR rate, 19.1%) and lobectomy patients (5-year CIR rate, 19.2%; P = 0.650). In the multivariable analysis using inverse probability of treatment weighting and surgical method, segmentectomy was not a significant predictor of worse CIR (P = 0.920).
Segmentectomy is feasible for clinically early-stage NSCLC irrespective of the presence of LY, V, PL or lymph node metastasis.
肺段切除术可为小尺寸非小细胞肺癌(NSCLC)提供具有肿瘤学可接受的结果。然而,在具有淋巴血管侵犯(LY)、血管侵犯(V)、胸膜侵犯(PL)和/或淋巴结转移等病理侵袭特征的 NSCLC 病例中,肺段切除术的可行性尚不清楚。
本研究纳入的患者(i)接受了具有 LY、V、PL 或病理性淋巴结转移等侵袭特征的 NSCLC 行肺叶切除术或肺段切除术;(ii)术前 CT 显示为无淋巴结转移、以实性成分为主的肿瘤(实性成分占比>50%);(iii)肿瘤整体大小为 2cm 或更小;(iv)于 2010 年 1 月至 2019 年 12 月期间在 3 家机构中的任意一家就诊。比较肺段切除术和肺叶切除术患者的复发累积发生率(CIR)。
共纳入 321 例患者,其中 80 例行肺段切除术(24.9%),241 例行肺叶切除术(75.1%)。肺段切除术患者的 CIR(5 年 CIR 率为 17.2%)与肺叶切除术患者(5 年 CIR 率为 27.8%)之间无显著差异(P=0.135)。在倾向评分匹配队列中,肺段切除术患者的 CIR(5 年 CIR 率为 19.1%)与肺叶切除术患者(5 年 CIR 率为 19.2%)之间亦无显著差异(P=0.650)。在使用逆概率治疗加权和手术方法的多变量分析中,肺段切除术并不是 CIR 更差的显著预测因素(P=0.920)。
肺段切除术可用于临床早期 NSCLC,无论是否存在 LY、V、PL 或淋巴结转移。